Home

Incannex Healthcare Inc. - Common Stock (IXHL)

0.8610
+0.0310 (3.73%)

Incannex Healthcare Inc. is a biotechnology company focused on developing innovative therapies that harness the potential of cannabinoid-based medicine

The company is dedicated to conducting rigorous clinical research to create safe and effective treatments for a range of medical conditions, including pain, anxiety, and other illnesses. Incannex aims to navigate the evolving regulatory landscape and collaborate with medical professionals to bring cannabinoid solutions to patients, while also emphasizing the importance of scientific validation and patient safety in the pharmaceutical field.

SummaryNewsPress ReleasesChartHistoricalFAQ
Previous Close0.8300
Open0.8100
Bid0.8600
Ask0.9200
Day's Range0.8000 - 1.180
52 Week Range0.7300 - 3.630
Volume422,199
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & YieldN/A (N/A)
1 Month Average Volume44,974

News & Press Releases

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025
Dallas, Texas--(Newsfile Corp. - February 18, 2025) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on...
Via Newsfile · February 18, 2025
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2025
Dallas, Texas--(Newsfile Corp. - December 2, 2024) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate...
Via Newsfile · December 2, 2024
Pfizer, Moderna, Novavax Take A Beating After Trump Taps Kennedy To Head Up HHSinvestors.com
President-elect Donald Trump tapped widely known vaccine skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services.
Via Investor's Business Daily · November 15, 2024
Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL)
Dallas, Texas--(Newsfile Corp. - October 2, 2024) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners initiates their coverage on...
Via Newsfile · October 2, 2024
Incannex Secures $60M Financing To Drive Advances In Psychedelic And Cannabinoid Therapiesbenzinga.com
Incannex Healthcare secures $60M in financing from Arena Investors to support clinical trials for cannabinoid and psychedelic therapies.
Via Benzinga · September 10, 2024
Sleep Apnea Pill: Quantum Research Survey Shows Sleep Apnea Patients Seeking CPAP Alternatives
New York, New York--(Newsfile Corp. - September 9, 2024) - Quantum Research Group, LLC just published the results of a...
Via Newsfile · September 9, 2024
FDA Clears Incannex To Proceed With Phase 2 Psilocybin-Assisted Therapy Trial For Anxietybenzinga.com
FDA approves Incannex's Phase 2 trial for psilocybin-assisted psychotherapy in treating generalized anxiety disorder, following a successful review of the IND application.
Via Benzinga · August 5, 2024
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Mondayinvestorplace.com
We have the biggest pre-market stock movers that investors are going to want to start the trading week with on Monday morning!
Via InvestorPlace · July 1, 2024
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursdayinvestorplace.com
Pre-market stock movers are worth checking out on Thursday as we dig into all of the biggest news moving shares this morning!
Via InvestorPlace · June 27, 2024
FDA Experts Weigh In On Incannex's CannQuit-O With Feedback On CBD As Treatment For Opioid Use Disorderbenzinga.com
Incannex Healthcare Inc., a cannabinoid and psychedelic medicine biotechnology company, announced the successful completion of a pre-investigational new drug meeting with the U.S. Food and Drug Administration (FDA) regarding the development of CannQuit-O for the treatment of opioid use disorder (OUD).A number of FDA representatives shared insights on the CannQuit-O development program during the pre-IND teleconference in addition to providing recommendations on the proposed clinical development strategy.
Via Benzinga · May 7, 2024
Stonegate Healthcare Partners Releases Report on Potentially Transformative Therapies for Generalized Anxiety Disorder (GAD)
Dallas, Texas--(Newsfile Corp. - May 1, 2024) - Stonegate Healthcare Partners is pleased to...
Via Newsfile · May 1, 2024
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & Morebenzinga.com
Via Benzinga · April 17, 2024
Largest Psychedelic Drug Stocks Up Another 10% Last Week; Now Up 54% YTDtalkmarkets.com
The 5 constituents in the Psychedelic Compound-Based Drug Stocks Index were up 10.0%, on average, last week and are now up 53.9% YTD.
Via Talk Markets · April 12, 2024
March Recap: Largest Psychedelic Drug Stocks Up Another 5%talkmarkets.com
The 5 constituents in the munKNEE Psychedelic Compound-Based Drug Stocks Index were UP 5.4%, on average, in March and are now UP 39.9% YTD.
Via Talk Markets · March 30, 2024
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influencebenzinga.com
Via Benzinga · March 29, 2024
Psychedelic-Assisted Therapy Advancements Create A New Horizon For Mental Health In Coloradobenzinga.com
Psilocybin-assisted therapy shows promise in treating GAD. Denver trains first responders in psychedelic crisis intervention. Heroic Hearts Project supports veterans with PTSD through legal psychedelic therapy. Colorado's Natural Medicine Health Act is a model for integrating psychedelics into public health.
Via Benzinga · March 22, 2024
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And Morebenzinga.com
Via Benzinga · March 20, 2024
Psychedelic Compound-Based Drug Stock, Mind Medicine, Up 56% Last Weekpsychedelic-com
The FDA has granted breakthrough designation to Mind Medicine's program for the treatment of generalized anxiety disorder.
Via Talk Markets · March 11, 2024
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And Morebenzinga.com
Via Benzinga · March 4, 2024
Largest Psychedelic Compound-Based Drug Stocks Up 15% In February; Now Up 33% YTDtalkmarkets.com
The Psychedelic Compound-Based Drug Stocks Index was up 15.0% in February led by Incannex Healthcare which was up 55.1%.
Via Talk Markets · March 1, 2024
Psilocybin-Assisted Therapy Achieves Positive Clinical Trial Results For Treating Generalized Anxietybenzinga.com
Via Benzinga · February 28, 2024
What's Going On With Incannex Stock?benzinga.com
Incannex said that its Phase 2 Psi-GAD1 clinical trial of psilocybin in generalized anxiety disorder met its primary endpoint of demonstrating a large clinical effect in the psilocybin treatment group over the placebo group.
Via Benzinga · February 28, 2024
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Sessionbenzinga.com
Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results.
Via Benzinga · February 28, 2024
How I Swing Trade Via Strength With Recent Examplestalkmarkets.com
In this video, I explain how I avoid major losses, keep my losses small, and maximize gains. I also provide some recent trades as examples.
Via Talk Markets · February 25, 2024
Psychedelic Stocks Index Popped 8% Last Week, Led By Incannextalkmarkets.com
IXHL 's increase was based on the successful completion of an Investigational New Drug meeting with the U.S. Food and Drug Administration regarding the development of CannQuit-N for tobacco smoking cessation and relapse control.
Via Talk Markets · February 18, 2024